Mutual's colchicine product Colcrys approved for gout in US
This article was originally published in Scrip
Executive Summary
Mutual Pharmaceutical Company's Colcrys has become the first single-ingredient colchicine product approved by the US FDA for treatment of gout flares. The agency also licensed Colcrys for familial Mediterranean fever, an inherited inflammatory disorder, making it the first drug approved for this condition.